Dan Durham, Executive Vice President for Health Policy at the Biotechnology Innovation Organization, released the following statement regarding the recent decision by the Centers for Medicare and Medicaid Services (CMS) to approve the Tennessee Medicaid (TennCare) Section 1115 waiver demonstration:
"We are extremely disappointed that CMS has chosen to approve a waiver demonstration that will put Tennessee Medicaid (TennCare) patients at risk. This dangerous decision will jeopardize access to critical medicines for some of our most vulnerable patients. BIO believes CMS does not have the legal authority to approve the waiver and closed formulary and we will work to protect patient access to the life-saving medicines they need.”